Hyperpolarized carbon 13 MRI in liver diseases: Recent advances and future opportunities

Zheng Ye1,2 | Bin Song1 | Philip M. Lee3 | Michael A. Ohliger3 | Christoffer Laustsen2

INTRODUCTION

The liver plays an important role in blood filtration, substance storage and all metabolic processes in the body, especially in the regulation of glycolysis and gluconeogenesis. Aberrated metabolism is often directly linked to various liver pathological conditions. It is worth noting that chronic diffuse liver diseases, such as non-alcoholic fatty liver disease (NAFLD) and cirrhosis, are becoming global health concerns and require early diagnosis and proper management. Likewise, liver cancer is the fourth leading cause of cancer-related death in the world and imposes significant burdens on healthcare systems.

At present, histopathological assessment of hepatic tissues obtained by biopsy or resection remains the gold standard in most liver diseases. However, this invasive approach is prone to sampling error and may cause complications, which is less suitable for longitudinal studies, therefore requiring non-invasive tools. Medical imaging has been widely applied in the detection, diagnosis and monitoring of liver diseases, including computed tomography (CT), magnetic resonance imaging (MRI) and positron emission tomography (PET).

Received: 9 October 2021 | Revised: 20 January 2022 | Accepted: 4 February 2022

DOI: 10.1111/liv.15222

1 Department of Radiology, West China Hospital, Sichuan University, Chengdu, Sichuan, China
2 The MR Research Center, Department of Clinical Medicine, Aarhus University, Aarhus, Denmark
3 Department of Radiology and Biomedical Imaging, University of California, San Francisco, California, USA

Correspondence
Christoffer Laustsen, The MR Research Center, Department of Clinical Medicine, Aarhus University, Palle Juul-Jensens Boulevard 99, Aarhus N 8200, Denmark. Email: cl@clin.au.dk

Funding information
This study was supported by China Scholarship Council and NIDDK R01 115987.

Handling Editor: Luca Valenti

Abstract

Hyperpolarized carbon-13 magnetic resonance imaging (HP 13C MRI) is a recently translated metabolic imaging technique. With dissolution dynamic nuclear polarization (d-DNP), more than 10000-fold signal enhancement can be readily reached, making it possible to visualize real-time metabolism and specific substrate-to-metabolite conversions in the liver after injecting carbon-13 labelled probes. Increasing evidence suggests that HP 13C MRI is a potential tool in detecting liver abnormalities, predicting disease progression and monitoring response treatment. In this review, we will introduce the recent progresses of HP 13C MRI in diffuse liver diseases and liver malignancies and discuss its future opportunities from a clinical perspective, hoping to provide a comprehensive overview of this novel technique in liver diseases and highlight its scientific and clinical potential in the field of hepatology.

KEYWORDS

carbon 13, diffuse liver diseases, hyperpolarization, liver malignancy, magnetic resonance imaging

1 INTRODUCTION

The liver plays an important role in blood filtration, substance storage and all metabolic processes in the body, especially in the regulation of glycolysis and gluconeogenesis. Aberrated metabolism is often directly linked to various liver pathological conditions. It is worth noting that chronic diffuse liver diseases, such as non-alcoholic fatty liver disease (NAFLD) and cirrhosis, are becoming global health concerns and require early diagnosis and proper management. Likewise, liver cancer is the fourth leading cause of cancer-related death in the world and imposes significant burdens on healthcare systems.

At present, histopathological assessment of hepatic tissues obtained by biopsy or resection remains the gold standard in most liver diseases. However, this invasive approach is prone to sampling error and may cause complications, which is less suitable for longitudinal studies, therefore requiring non-invasive tools. Medical imaging has been widely applied in the detection, diagnosis and monitoring of liver diseases, including computed tomography (CT), magnetic resonance imaging (MRI) and positron emission tomography (PET).
Images from CT and conventional proton MRI mainly reflect structural and functional changes and cannot assess altered metabolism. Non-invasive monitoring of metabolic changes may provide insight into understanding impaired or cancerous hepatic tissues. Currently, PET is the only imaging modality that provides metabolic information in the clinical setting. It enables visualization of hepatic glucose uptake by injecting $^{18}$F labelled fluorodeoxyglucose (FDG) or fluoro-2-deoxy-D-galactose (FDGal) but fails to capture downstream metabolism that is often crucial in many pathological circumstances. Hyperpolarized (HP) MRI with carbon-13 ($^{13}$C) labelled substrates, also known as HP $^{13}$C MRI, can uniquely track real-time metabolic uptake and conversion in vivo, which would be valuable in liver diseases.

With the invention of dissolution dynamic nuclear polarization (d-DNP), dramatically enhanced signal of HP $^{13}$C MRI can be detected within seconds and up to minutes after injection. By mapping the dynamic conversion between HP $^{13}$C substrates and their metabolic products, for example, [1-$^{13}$C]pyruvate to [1-$^{13}$C]lactate or [1-$^{13}$C]alanine, researchers can obtain additional data beyond routine imaging modalities and form a better understanding of liver pathogenesis. Recent evidence indicates that this technique holds great promise in both diffuse liver diseases and liver malignancies, with special focus on detection and diagnosis; assessment of disease progression and prediction of therapeutic responses. Therefore, this paper aims to provide a comprehensive overview of HP $^{13}$C MRI in liver diseases by introducing the workflow of this technique and then reviewing its recent applications in diffuse liver diseases and liver malignancies. More importantly, we will discuss the future opportunities in this field from a clinical perspective, hoping to highlight the scientific potential of this novel technique and foster its clinical translations in hepatology.

### Key points

1. Hyperpolarized $^{13}$C MRI is an emerging and promising technique in diffuse liver diseases and liver malignancy. It allows for real-time assessment of hepatic metabolism in vivo and has been applied in detecting, monitoring progression and assessing treatment efficacy of liver diseases.

2. Great efforts should be made to optimize the workflow of hyperpolarized $^{13}$C MRI and foster its clinical translations, which also introduces future opportunities in this field.

#### 2 | HEPATIC METABOLISM AND PYRUVATE

The liver is an essential metabolic organ in the body, responsible for the metabolism of carbohydrates, lipids and proteins, with pyruvate serving as the key branch point of multiple metabolic pathways. As a highly biologically relevant probe, HP [1-$^{13}$C]pyruvate is rapidly taken up into hepatocytes following intravenous injection and metabolized into either [1-$^{13}$C]lactate via lactate dehydrogenase (LDH) or [1-$^{13}$C]alanine via alanine aminotransferase (ALT) in the cytoplasm. HP [1-$^{13}$C]pyruvate can also be transported into the mitochondria and converted by pyruvate dehydrogenase (PDH) into acetyl-coenzyme A and [1$^{13}$C]CO$_2$, which is in rapid equilibrium with [1$^{13}$C]bicarbonate. Based on the different resonance frequencies (i.e. chemical shift) of the substrate and products, the signals of injected pyruvate and its metabolites can be detected on HP $^{13}$C MRI.

Hepatic metabolism is tightly controlled by a variety of factors and it changes under different liver pathological conditions. HP [1-$^{13}$C]pyruvate is to date the only probe available for human examinations and thus widely studied. It has been predominantly used to interrogate metabolism associated with early and precise liver disease diagnosis and disease progression evaluation. For example, the activity of ALT is usually elevated in patients with liver injury, which can lead to the increase of [1-$^{13}$C]alanine. Abnormal glucose and lipid metabolism also often occurs in NAFLD patients. In addition, metabolic reprogramming in hepatocellular carcinoma (HCC), especially the increased lactate production, can be identified by HP $^{13}$C MRI. Compared to current imaging methods, HP $^{13}$C MRI provides unique metabolic information about pathway-specific alterations without using ionizing radiation. This additional metabolic information opens up possible novel diagnostic and therapeutic opportunities; therefore, the multiparametric MRI examination with $^1$H and $^{13}$C imaging will likely be the future direction for the comprehensive assessment of liver diseases (Figure 1).

#### 3 | WORKFLOW OF HYPERPOLARIZED CARBON 13 MRI

The workflow of HP $^{13}$C MRI is summarized in Figure 2 and can be simply divided into following four steps. The first step is to formulate the $^{13}$C-enriched compounds by mixing $^{13}$C substrate, typically [1-$^{13}$C]pyruvate and a radical with unpaired electrons. This preparation process should be conducted in a sterile environment and with the help of commercially available pharmacy kit if it is a human clinical study. Following this procedure, the sample is then placed into the polarizer to achieve hyperpolarization, where the solution experiences microwaves, cold temperature (0.8 K) and strong magnetic field (5T). Based on the d-DNP technique, the unpaired electron spins can be polarized to nearly 100% in such environment, and the high polarization can be transferred to the $^{13}$C isotope in $^{13}$C-enriched pyruvate molecule. Current clinical polarizers can reach up to 50% polarization of [1-$^{13}$C]pyruvate (MR signal is enhanced >10000 times), which takes approximately 120 min. After the sample is polarized, a quality-control module measures its polarization level, pH, temperature, radical and...
pyruvate concentrations before injection to ensure it is safe for clinical use. As for the image acquisition, specialized $^{13}$C radiofrequency coils are used for imaging the $^{13}$C hyperpolarized molecule signals, preferably dual-tuned $^1$H/$^{13}$C coils, allowing both anatomical and hyperpolarized $^{13}$C imaging in a clinical workflow. Prior to injection, the scanner is calibrated for carbon imaging, including careful shimming of the main magnetic field and adjustment of the radiofrequency centre frequency. Following the injection of the HP $^{13}$C substrate, the subject is imaged with optimized fast $^{13}$C sequences (typically less than 2 min), which would acquire the uptake and subsequent metabolic conversion in the liver parenchyma. In order to evaluate focal disease, imaging methods, such as chemical shift imaging (CSI) and spectral spatial excitation imaging, are the preferred option for liver applications. Finally, with the post-processing algorithms, the acquired data can be quantified and visualized for the exploration of metabolic alterations. One common method is to express the total signal of downstream metabolites as a fraction of the signal from the injected probe. Alternatively, quantitative metabolic measures such as the apparent rate constant for pyruvate-to-lactate conversion ($k_{PL}$) can also be calculated and quantify changes in specific drivers of the glycolysis.

Current technical challenges in HP $^{13}$C MRI include the non-renewable HP $^{13}$C signal, limited spatial resolution as well as unstandardized imaging procedures. The complexity and high expense of this technique may also limit its role as a primary screening and diagnostic tool in clinical practice.

4 | RECENT ADVANCES

A summary of recent HP $^{13}$C MRI studies on diffuse and focal liver diseases is shown in Table 1 and Table 2. Hereinafter, we will review the results and describe the possible clinical applications of HP $^{13}$C MRI in liver injury, liver fibrosis and fatty liver diseases, as well as liver malignancies.
Liver injury is commonly induced by excess alcohol consumption, drug intake and virus infection, which may progress to liver failure without timely intervention and thus requires early detection.\textsuperscript{21–23} Most liver injuries are initiated by disturbances in cellular metabolism and present as a group of damaged hepatocytes in histology. As revealed by recent studies,\textsuperscript{24,25} the changed metabolism of liver impairment can be identified by HP $^{13}$C MRI. By intraperitoneally injecting CCl$_4$ in rats, Josan et al.\textsuperscript{24} established an inflammatory liver injury model and subsequently acquired the dynamic metabolic maps on them. They found both alanine/pyruvate and lactate/pyruvate ratios were higher in CCl$_4$-treated group compared with control group and noted elevated activity of the ALT and LDH respectively. Such ability of HP $^{13}$C MRI greatly supplements the deficiency of routine clinical blood tests for measuring ALT and LDH, as it can observe the actual changes of corresponding enzymatic activities and its spatial distribution. Similarly, Kim et al.\textsuperscript{25} also suggested the levels of lactate and alanine as biomarkers in a preclinical hepatotoxicity model with administration of 1,3-dichloro-2-propanol. In animals administered the toxic chemical, liver damage was shown histologically, including haemorrhage in hepatic parenchyma, inflammatory cell infiltration, vacuolation as well as degeneration and necrosis of hepatocytes. More importantly, a significant increase of the lactate to total carbon ratio and alanine to total carbon ratio was reported. These works confirmed the feasibility of HP $^{13}$C MRI in detecting liver injury, which indicates strong potential for clinical translation as it may
help to monitor the disease progression and provide opportunity for treatments.

In addition, liver damage can be caused by ischaemia reperfusion injury (IRI). Typically, vascular clamping is often required in major liver resection or liver transplantation to avoid excessive bleeding, which can induce a period of hepatic ischaemia. When the blood flow is restored, the reperfusion could worsen cell injury on the already ischaemic liver and precipitate tissue necrosis. This phenomenon is called hepatic IRI and can lead to acute liver failure. Generally, alterations in biochemical and histopathological characteristics along with elevated levels of transaminases would occur during hepatic IRI, reflecting hepatocyte injury or stress. With the application of HP 13C MRI, the additional metabolic changes of hepatic IRI can be captured in real time and associated with increased vulnerability of hepatic function to IRI. They considered higher alanine level but decreased pyruvate levels, compared with both sham-operated controls and rats before IRI. They considered higher alanine level as an indicator of increased vulnerability of hepatic function to IRI and associated the higher lactate level with increased LDH activity.

Repeated wound-healing response of liver injury can lead to accumulation of extracellular matrix and cause liver fibrosis, which progressively restricts normal hepatic regeneration, thereby increasing the risk of hepatic dysfunction, portal hypertension and even HCC. Early or intermediate liver fibrosis can be reversed with elimination of causative injury triggers and the application of anti-fibrotic drugs, introducing the urgent need for its early detection and accurate staging in a non-invasive manner. Recently, Moon et al. applied HP 13C MRI in a liver fibrosis animal model induced by thioacetamide. Their findings demonstrated elevated levels of lactate and alanine in fibrosis groups compared to normal control group, validating the potential alterations of glycolysis and gluconeogenesis in hepatic fibrogenesis, and also suggested the ratios of alanine/pyruvate and alanine/total carbon as the indicators in assessing the severity of liver fibrosis. Moreover, negative correlation was presented between the level of HP 13C metabolites and pseudo-diffusion coefficient (D*) derived from intravoxel incoherent motion (IVIM), which reflected perfusion-related information and was widely used to evaluate liver fibrosis. Hence, in conjunction with functional imaging parameters, one could expect the future role of HP 13C MRI in detecting and staging liver fibrosis and aiding appropriate clinical therapeutic decisions.

### 4.1.2 Fatty liver diseases

NAFLD is characterized by excessive accumulation of fat in the liver and is histologically classified as non-alcoholic fatty liver (NAFL) and non-alcoholic steatohepatitis (NASH), with the latter presenting hepatic inflammation and oxidative stress. Owing to the dramatic changes in lifestyles and diet, the prevalence of NAFLD has increased in the past decades and has posed serious health and economic burdens worldwide. Accurate stratification of liver steatosis

### Table 2: Summary of HP 13C MRI in liver malignancies

| Authors         | Year | Probes                    | Subjects                        | Possible clinical applications               |
|-----------------|------|---------------------------|---------------------------------|---------------------------------------------|
| Gallagher et al | 2008 | [5-13C] glutamine         | HepG2                           | Assessment of tumour proliferation          |
| Yen et al       | 2010 | [1-13C] pyruvate          | Rats with Morris hepatoma       | Detection of early HCC                     |
| Hu et al        | 2011 | [1-13C] pyruvate          | Mice with Myc gene-driven liver cancer | Detection of early HCC               |
| Darpolor et al  | 2011 | [1-13C] pyruvate          | Rats with Morris hepatoma       | Detection of early HCC                     |
| Von Morze et al | 2011 | [13C] urea                 | Tumour-bearing mice from a transgenic model | Assessment of tumour perfusion          |
| Menzel et al    | 2013 | [1-13C] pyruvate          | Rats with Morris hepatoma       | Combination with PET                        |
| Cabella et al   | 2013 | [5-13C] glutamine          | McA-RH7777, rats with Morris hepatoma | Evaluation of drug response                   |
| Jensen et al    | 2015 | [1,3-13C2] EAA             | HepG2, McA-RH7777, rats with Morris hepatoma | Detection of early HCC                     |
| Düwel et al     | 2016 | [13C,15N2] urea, [1-13C] pyruvate, [1,4-13C2] fumarate | Rats with Morris hepatoma       | Evaluation of TAE response                  |
| Perkons et al   | 2020 | [1-13C] pyruvate          | HepG2, HR2, rats with DEN-induced HCC | Evaluation of TAE response                  |
| Chen et al      | 2020 | [1-13C] pyruvate          | Patients with metastatic liver cancer | Evaluation of drug response                  |
| Bliemsrieder et al | 2021 | [1-13C] pyruvate          | Rats with DEN-induced HCC       | Assessment of HCC phenotypes               |

Note: Morris hepatoma model was built by injecting McA-RH7777 cells in rats; HR2 indicated the tumour cells derived from DEN-induced HCC rats. Abbreviations: DEN, diethylnitrosamine; EAA, ethyl acetoacetate; HCC, hepatocellular carcinoma; HepG2, human hepatoma cells; PET, positron emission tomography; TAE, trans-arterial embolization.
and early identification of NAFLD are of utmost importance in disease management, making the novel non-invasive imaging technique, HP $^{13}$C MRI, a promising tool in this context. Consecutive studies from Jeong’s group initially explored the time course changes of HP $^{13}$C metabolites in obese and NAFLD rats induced by high-fat diet (HFD), suggesting the increased levels of alanine and lactate as the useful biomarkers of fatty liver diseases.$^{34,35}$ Subsequently, Smith et al. quantified the metabolic changes in NAFLD and normal pigs by measuring time to peak (TTP) of HP $^{13}$C pyruvate and its metabolites.$^{51}$ They noted the decreased liver lactate TTP in $^{13}$C spectra in NAFLD pigs, indicating an increased rate of lactate production and a disturbance in liver lipid synthesis. Based on these findings, it is anticipated to incorporate HP $^{13}$C MRI in clinical practice to properly understand the underlying mechanisms of NAFLD and eventually guide clinicians to better manage this disease and help its reversal.

A growing body of evidence suggests that NAFLD is greatly associated with metabolic dysfunctions, such as insulin resistance and type 2 diabetes mellitus (T2DM)$^{36}$; therefore, the nomenclature was recently revised to metabolic associated fatty liver disease (MAFLD).$^{37}$ allowing for a wider definition of the disease. A pioneer study by Lee et al. successfully utilized HP $^{13}$C MRI to determine the changes in hepatic gluconeogenesis in HFD-induced mouse model of T2DM.$^{12}$ Particularly, compared with control group, increased exchange rates of pyruvate to aspartate and malate were demonstrated in HFD mice, with the former exchange rate exhibiting significant correlation with gluconeogenic pyruvate carboxylase (PC) activity, suggesting the critical role of the PC pathway in hepatic glucose production. What is more, they showed that HFD mice treated with metformin displayed lower aspartate and malate signals as well as decreased exchange rates from pyruvate, agreeing with downregulated gluconeogenesis. Encouraged by the capability of HP $^{13}$C MRI in probing metabolism that were previously inaccessible in other imaging modalities, we believe this non-invasive technique may facilitate identification of novel therapeutic targets and longitudinal assessment of therapeutic response in MAFLD patients.

Given the adverse consequences of NASH, namely liver cirrhosis and cancers, it is crucial to recognize the disease at an early stage and initiate corresponding medical treatments. The ongoing research for pharmacological treatment and therapeutic targets necessitates an understanding of the metabolic pathways in this field.$^{38}$ Fortunately, HP $^{13}$C MRI offers additional $^{13}$C probes alternative to pyruvate, such as $[1,1-^{13}$C$]_{2}$dehydroascorbic acid (DHA), which can be converted to Vitamin C (VitC) in the liver and used for exploring redox reaction in vivo.$^{39}$ Wilson et al. induced a NASH animal model with methionine-choline deficient (MCD) diet and then intravenously injected HP $^{13}$C labelled DHA in them.$^{40}$ In relative to control group, a 49% reduction in the ratio of DHA to VitC was observed in mice with MCD diet, accompanied by hepatic fat deposition. Notably, the alterations in metabolic ratios returned to baseline when placing the previous MCD animals on a normal diet for 1 week. Even though the exact metabolic and catalytic process can be difficult to identify under the complexity of the intracellular redox network, there is no doubt that HP $^{13}$C MRI has broadened the current knowledge of NASH-related metabolic abnormalities, which could possibly introduce novel therapeutic chances in near future.

## 4.2 Liver malignancy

### 4.2.1 Detection of early HCC

Typical hepatocarcinogenesis is considered as a stepwise development, from regenerative nodules, to dysplastic nodules and early HCC, and finally to overt HCC.$^{41}$ This multistep progression is accompanied by morphological, histopathological and haemodynamic changes, as well as altered metabolism.$^{42-46}$ However, since a majority of HCCs arise in the cirrhotic background, which consists of a heterogeneous structure and displays as multiple mass-like nodules,$^{45}$ the detection of small or early HCC can be extremely challenging with conventional imaging modalities, making metabolic imaging a potential tool in this regard. By investigating an animal model of Myc gene-driven liver cancer with HP $^{13}$C MRI, Hu et al. found that tumour metabolic alterations preceded any observable morphological and histological changes.$^{46}$ More specifically, their findings showed a significant increase in the conversion of pyruvate to alanine in pre-tumor tissues, which was absent in either normal tissues or established tumours, and they also indicated the precancerous regions with the most abundant alanine signal tended to eventually develop into tumours. In clinical scenarios, most HCC patients are diagnosed at an advanced stage and have limited treatment options; therefore, these promising results of HP $^{13}$C MRI in HCC early detection are of great importance, which provides the possibility of capturing early tumorigenesis and identifying it before tumour formation.

Consistent with prior knowledge of the Warburg effect that cancer cells prefer glycolysis rather than oxidative metabolism despite the adequate oxygen supply,$^{57}$ HCC is characterized by increased flux of pyruvate to lactate, which can be readily detected by HP $^{13}$C MRI.$^{46,48}$ Moreover, significant alanine production was also noted in HCC cells and animal model with implanted Morris hepatoma in a study from Darpolor et al.$^{49}$ They reported increased lactate and alanine in tumour tissues and attributed these changes to elevated LDH and ALT activity. Interestingly, the conversion from pyruvate to alanine significantly superseded that of pyruvate to lactate in their study, which was in good agreement with a previous literature with same animal model.$^{50}$ However, controversial results were demonstrated in studies with different animal models$^{46}$ or different tumour-implanted locations,$^{48}$ showing higher lactate signal than alanine in tumour tissues, which may have been owing to the difference in tumour growth microenvironment and vascularization. Thus, although these metabolic signatures from HP $^{13}$C MRI may help to unveil the underlying mechanisms of HCC development and facilitate tumour detection and differential diagnosis, metabolic aberrations in patients with primary liver malignancy remain unknown and require extended investigations in the future.

More recently, new HP $^{13}$C probe, $[1,3-^{13}$C$]_{2}$ethyl acetoacetate (EAA), has been reported feasible in imaging the metabolism in rats
with implanted HCC. It is generally acknowledged that the concentrations and activities of carboxylesterases, an enzyme that turn EAA to acetoacetate (AA), are lower in cancer cells compared to the corresponding normal cells. In particular, as shown by Jensen et al., approximately four times higher substrate-to-product signal ratio was observed in tumour tissues when compared to the surrounding healthy tissue. Furthermore, in comparison with the images from commonly used pyruvate, the contrast to noise ratio of images was significantly improved by using EAA. These findings of new metabolic biomarkers in HP 13C MRI are promising because they offer an opportunity to develop novel strategies for enhancing image contrast between cancerous and normal tissues and ultimately improving the detection of small and early cancer lesions.

4.2.2 Assessment of biological characteristics

Although most HCCs have similar imaging features, different biological characteristics do exist in HCCs, which can significantly affect treatment efficacy and prognosis. As pyruvate and its products showed great potential in identifying tumour aggressiveness in various tumour entities, the various biological characteristics in HCCs could be noninvasively evaluated with the help of HP 13C MRI. In order to better delineate the metabolic phenotyping of HCCs and explore its correlation with tumour biological behaviours, Bliemsrieder et al. recently conducted a sophisticated study, firstly inducing endogenous HCC in rats, and then re-implanting the extracted tumour cells in another group of nude rats. Their findings showed different lactate-to-alanine signal ratios of endogenous HCCs and higher lactate signal in re-implanted tumours derived from high lactate-to-alanine ratios tumour cells. Additionally, they suggested that HCCs with high lactate-to-alanine ratios may be more aggressive because high lactate production was reported to be associated with higher biological aggressiveness in cancers. In other words, metabolic alterations detected by HP 13C MRI, especially glucose metabolism and lactate production, provide more insights into biological characteristics of liver malignancy and therefore may promote the development of additional diagnostic and prognostic biomarkers.

Alternative HP 13C probes were also introduced in the evaluation of tumour biological characteristics. Previous evidence suggested that HCCs with highly proliferated properties tend to be more aggressive, leading to early recurrence and poor prognosis, which makes [5-13C] glucose a promising substrate in HP 13C MRI. Physiologically, glutamine can be converted to glutamate by intramitochondrial glutaminase. It plays an essential role in tumour cell metabolism and is related to cell proliferation. An initial study confirmed the feasibility of HP 13C MRI in imaging the conversion from glutamine to glutamate in human hepatoma cells, which may allow for the assessment of tumour proliferation and the prediction of prognosis in patients with HCC in the future. Apart from metabolically active HP 13C substrates, inactive agents, such as [13C] urea, can be possibly used for assessing biological characteristics in liver malignancy with its promising results in perfusion imaging. Von Morze et al. found significant differences in regional perfusion characteristics in cancerous tissues by injecting HP [13C] urea in a preclinical HCC model. In particular, a 19% reduction in mean blood flow was observed in tumours, whereas 26% elevation was found in the tumour rim. These results and the described method were clinically relevant because tumours typically exhibit altered blood flow and perfusion patterns owing to abnormal neovascularization. Therefore, with the obtained perfusion information by HP 13C MRI, researchers could probably predict the biological behaviours of HCC and patients may finally benefit from individual pre-therapeutic tumour assessment.

4.2.3 Evaluation of treatment response

Unresectable HCCs are usually recommended for locoregional treatment, including transarterial embolization (TAE) with or without chemo drugs, or systemic therapy. Nevertheless, frequent local recurrence and metastasis after treatment can be problematic in refractory HCCs, which results in poor overall survival and high mortality in patients. Current imaging paradigms mostly provide information on tumour volume and vascularity for the assessment of treatment efficacy, which fails to detect the latent tumour cells and emphasizes the need for advanced metabolic imaging methods, such as HP 13C MRI. Recently, Perkins and his colleagues found that latent HCC cells activated metabolic reprogramming to survive TAE-induced ischaemia. Notably, decreased anabolism and increased lactate production were observed in latent HCC undergoing TAE-induced ischaemia both in vitro and in vivo. In addition, as illustrated in the representative images in their study, conventional proton imaging failed to detect viable tumour cells with absent contrast enhancement, while HP 13C MRI enabled the direct detection of persistent metabolism in surviving HCC cells at the tumour periphery. Together, these inspiring findings hold significant implications for evaluating therapeutic response and guiding subsequent interventions in patients with unresectable HCC and help to improve their clinical outcomes.

Pathologically, necrosis is usually the consequence of embolizing feeding hepatic arteries and depriving tumours from nutrients in TAE treatment, which can be easily detected by using another HP 13C probe, [1,4,13C2]fumarate. In general, the conversion rate and concentration of fumarate and its metabolite (i.e., malate) would rapidly change when the tumour cells are in a necrotic condition without intact membrane. To simultaneously collect the information about tumour metabolism, perfusion and necrosis after TAE therapy, Düwel et al. performed a HP 13C MRI experiment with multiple HP substrates, including pyruvate, urea and fumarate, in a rat model with orthotopic HCC. As expected on TAE treatment, decreased urea and pyruvate signals, as well as an increased apparent conversion rate from pyruvate to lactate were observed in their study, indicating reduced perfusion and increased hypoxic glycolysis. Furthermore, there was a significant elevation of malate after
embolization and the ratio of total malate to total fumarate greatly correlated with the histological necrosis level, with correlation coefficient of 0.86. Hence, when integrating various information provided by different 13C probes, HP 13C MRI may be able to assess the treatment efficacy of HCC and identify beneficiary patient cohort for specific treatments and even aid the development of novel therapeutic concepts.

Given the close relationship between pharmacologic action of chemotherapy and metabolic pathways, it is possible to utilize HP 13C MRI to evaluate chemotherapeutic response of liver malignancy. A recent pilot study investigated the dynamic metabolism in a prostate cancer patient with liver metastasis before and after chemotherapy. As shown in their research, the pyruvate-to-lactate conversion rate of the metastatic liver lesion decreased from 0.026 to 0.015 s⁻¹ (42% reduction), and the tumour size reduced from 19.3 mm to 11.8 mm (39% reduction) 2 months after the initiation of chemotherapy. In addition, Cabella et al. proposed a novel preparation method for HP [5-13C] glutamine and confirmed its ability in measuring the response to chemotherapy in HCC cells. In light of these findings, HP 13C MRI may become the solution to current unmet clinical dilemma of liver cancer, which can be especially helpful in guiding the development of new chemotherapeutic and targeted drugs, and acting as a robust biomarker in longitudinal follow-up trails.

## 5 | FUTURE OPPORTUNITIES

HP 13C MRI provides a fundamentally new way of looking at patients with liver diseases. By identifying intracellular metabolism, we can expect to better understand the biology of diffuse liver diseases and therefore better manage them. These specific metabolic markers can be the non-invasive surrogate in monitoring the disease progression and assessing therapeutic response. As for liver malignancies, the information on downstream metabolism offers the possibility of detecting early HCC before observable morphological changes and understanding its pathogenic mechanism. Such metabolic biomarkers can also help assess biological behaviours of tumours and aid personalized treatment strategies. For example, the metabolic alterations in tumour and peritumoral parenchyma may guide surgeons to determine the actual resected areas. In addition, based on the previous findings, HP 13C MRI can be a powerful tool in evaluating the treatment efficacy and predicting the clinical outcomes of patients. Despite the encouraging results and great potential of this technique in both diffuse and focal liver diseases, further research is still warranted to optimize the workflow.

Continuing works on the imaging hardware and acquisition sequences are needed to improve the sensitivity of HP 13C MRI and increase its clinical applicability. Besides the development and technical improvements of dual-tuned 1H/13C volume coils for abdominal organs, works on receive surface coils with short coil-to-sample distance and optimal coil combinations are currently ongoing. Additionally, in order to further prevent signal loss and capture rapid metabolic conversion without significant motion artefacts, new fast acquisition is required to obtain volumetric and dynamic HP MR data of the liver, preferably towards whole liver coverage, sub-centimetre spatial resolution and higher temporal resolution (e.g., 1 s for pyruvate and 3 s for its metabolites). With the combination of parallel imaging technique, compress sensing and spiral trajectories, it is believed that current acquisition methods will advance to these expectations in the near future. More recently, a novel post-processing pipeline was proposed to reduce background noise in HP spectra and increase the accuracy of kinetic estimations in patients with liver tumours, emphasizing the needs for new analysis techniques with improved spectral SNR and more accurate measurements.

In view of the heterogeneous nature of liver diseases, especially liver malignancies, the combination of HP 13C MRI with multiphasic and multiparametric 1H imaging, as well as multimodal findings could be of great significance for personalized medicine in the future. For

### Table 3: Established and promising hyperpolarized 13C probes in liver diseases

| Molecule | Pathways / functions | Possible applications | References |
|----------|----------------------|-----------------------|------------|
| [1-13C] pyruvate | Glycolysis and ALT, LDH, PDH activity | Diffuse liver diseases and liver cancers | 10-15, 24, 25, 29, 34, 35, 46, 48-50, 56 |
| [1-13C] dehydroascorbic acid | Redox status | Liver injury and NASH | 40 |
| [1,3-13C]2 ethyl acetooacetate | Carboxylesterase activity | Liver cancers | 51 |
| [5-13C] glutamine | Glutaminolysis, cellular proliferation | Liver cancers | 58, 67 |
| [13C] urea or [13C, 15N2] urea | Perfusion | Liver fibrosis and liver cancers | 14, 59 |
| [1,4,13C]2 fumarate | Cellular necrosis | Liver cancers | 14 |
| [2-13C] dihydroxyacetone | Gluconeogenesis | NAFLD | 75, 76 |
| [1-13C] alanine | Redox status | Liver injury and NASH | 77 |
| [1,13C, U-1H2] ethanol | Aldehyde dehydrogenase activity | Alcoholic liver disease and liver cancers | 78 |
| [1,13C]L-lactate | Pyruvate carboxylase activity | NAFLD | 79 |

Abbreviations: ALT, alanine transaminase; LDH, lactate dehydrogenase; NAFLD, non-alcoholic fatty liver disease; NASH, non-alcoholic steatohepatitis; PDH, pyruvate dehydrogenase.
example, the liver-specific gadolinium contrast-agent can not only provide valuable multiphasic information about haemodynamic changes but also selectively suppress normal hepatocyte contributions to hyperpolarized 13C MRI signal, which could be applied to separate the metabolic signals arising from the small tumours and surrounding normal hepatocytes.72 On the other hand, a multiparametric imaging approach with both HP 13C MRI and diffusional or other functional sequences is anticipated to monitor the therapeutic effects in liver diseases.10,29,73 Besides, the combination of HP 13C MRI and PET was shown promise in a rat model with HCC.48 This multimodal technique was named as HyperPET,74 and it is believed to provide complementary information and allow for better evaluation of the biological behaviours and treatment response in liver cancers.

In addition to the widely investigated pyruvate, a number of different 13C substrates have been proposed and tested promising in the liver, including earlier mentioned DHA, EAA, glutamine, urea and fumarate, as well as dihydroxyacetone,75,76 alanine77 and several others78,79 (Table 3), providing further details on the metabolism under different hepatic pathologies. As reported, dihydroxyacetone is sensitive to dysregulation of hepatic gluconeogenesis and glycolysis25,76 and may be used to investigate metabolic diseases such as NAFLD or cirrhosis in a non-invasive manner. Furthermore, alanine has a potential role in measuring hepatic redox reaction, which could be utilized in the evaluation of liver damage.77 Moreover, simultaneous co-polarization and co-injection of multiple compounds was recently shown feasible in a preclinical HCC model.14 This is significant because it enables the assessment of several cellular processes at the same time and optimizes the workflow and could possibly become a future research direction. Further work with higher and faster polarizations and simplified delivery of sterile HP probes are also needed to facilitate the clinical adoption of this technique.

Last but not least, extended preclinical studies of liver metabolism are still needed to bridge the translational gap of HP 13C MRI. Currently, there is an ongoing clinical trial aiming to explore the effect of nutritional state and fatty liver on TCA cycle in healthy subjects and patients with fatty liver diseases by using HP 13C pyruvate injection.80 Nevertheless, owing to the limited human studies in real clinical scenarios, multicentre trails are necessary to better standardize this technique and improve its robustness, reliability and efficiency.3 Hopefully, with the help of multiple collaborations, HP 13C MRI can be integrated as a short (5-min) add-on into the routine MRI examination in the coming future.

6 | CONCLUSIONS

HP 13C MRI is an emerging and promising technique in both diffuse liver diseases and liver malignancies. It allows for real-time visualization of hepatic metabolism and enzymatic conversions and is of significant potential in detecting liver diseases, monitoring its progression and assessing the treatment efficacy. There are still unresolved barriers of this technique on the road to clinical transformation, but it also brings future research opportunities in this field. With the improvement of this technique and optimization of the workflow, HP 13C MRI is expected to become a powerful tool for the diagnosis and management of liver diseases in clinical practice.

CONFICT OF INTEREST

All authors declare no conflict of interest.

DATA AVAILABILITY STATEMENT

Data sharing is not applicable to this article as no new data were created or analysed in this study.

ORCID

Zheng Ye https://orcid.org/0000-0001-6715-0183

Bin Song https://orcid.org/0000-0001-7007-6367

Philip M. Lee https://orcid.org/0000-0002-5783-1599

REFERENCES

1. Adeva-Andanya Maria M, Pérez-Felpete N, Fernández-Fernández C, Donapetry-García C, Pazos-García C. Liver glucose metabolism in humans. Biosci Rep. 2016;36(6):e00416.

2. Chen Z, Tian R, She Z, Cai J, Li H. Role of oxidative stress in the pathogenesis of nonalcoholic fatty liver disease. Free Radiac Biol Med. 2020;152:116-141.

3. Ray K. NAFLD—the next global epidemic. Nat Rev Gastroenterol Hepatol. 2013;10(11):621.

4. Bertuccio P, Turati F, Carlioli G, et al. Global trends and predictions in hepatocellular carcinoma mortality. J Hepatol. 2017;67(2):302-309.

5. Torres LA, Bray F, Siegel RL, Ferlay J, Lortet-Tieulent J, Jemal A. Global cancer statistics, 2012. CA Cancer J Clin. 2013;65(2):87-108.

6. Regev A, Berho M, Jeffers L, et al. Sampling error and intraobserver variation in liver biopsy in patients with chronic HCV infection. Am J Gastroenterol. 2002;97(10):2614-2618.

7. Wang ZJ, Ohliger MA, Larson PEZ, et al. Hyperpolarized C-13 MRI: state of the art and future directions. Radiology. 2019;291(2):273-284.

8. Kurhanewicz J, Vigneron DB, Ardenkjaer-Larsen JH, et al. Hyperpolarized C-13 MRI: path to clinical translation in oncology. Neoplasia. 2019;21(1):1-16.

9. Knowles BR, Friedrich F, Fischer C, Ladd ME, Paech D. Beyond T2 and 3T: new MRI techniques for clinicians. Clin Transl Radiat Oncol. 2019;18:87-97.

10. Moon C-M, Shin S-S, Heo S-H, et al. Metabolic changes in different stages of liver fibrosis: in vivo hyperpolarized C-13 metabolic imaging detects latent hepatocellular carcinoma domains surviving locoregional therapy. Hepatology (Baltimore, MD). 2013;57(2):515-524.

11. Smith LM, Pitts CB, Friedrich CR, et al. In vivo magnetic resonance spectroscopy of hyperpolarized 1-13C pyruvate and proton density fat fraction in a Guinea pig model of non-alcoholic fatty liver disease development after life-long Western diet consumption. J Magn Reson Imaging. 2021;54:1404-1414.

12. Lee P, Leong W, Tan T, Lim M, Han W, Radda GK. In vivo hyperpolarized carbon-13 magnetic resonance spectroscopy reveals increased pyruvate carboxylase flux in an insulin-resistant mouse model. Hepatology (Baltimore, MD). 2013;57(2):515-524.

13. Perkins NR, Kiever RM, Noji MC, et al. Hyperpolarized metabolic imaging detects latent hepatocellular carcinoma domains surviving locoregional therapy. Hepatology (Baltimore, MD). 2020;72(1):140-154.

14. Duwel S, Durst M, Gringeri CV, et al. Multiparametric human hepatocellular carcinoma characterization and therapy response evaluation by hyperpolarized (13)C MRSI. NMR Biomed. 2016;29(7):952-960.
15. Chen H-Y, Aggarwal R, Bok RA, et al. Hyperpolarized 13C-pyruvate MRI detects real-time metabolic flux in prostate cancer metastases to bone and liver: a clinical feasibility study. *Prostate Cancer Prostatic Dis*. 2020;23(2):269-276.

16. Khomich O, Ivanov AV, Bartosch B. Metabolic hallmarks of hepatic stellate cells in liver fibrosis. *Cell*. 2019;9(1):24.

17. Lu Q, Tian X, Wu H, et al. Metabolic changes of hepatocytes in NAFLD. *Front Physiol*. 2021;12:710420.

18. De Matteis S, Ragusa A, Marisi G, et al. Aberrant metabolism in hepatocellular carcinoma provides diagnostic and therapeutic opportunities. *Oxid Med Cell Longev*. 2018;2018:7512159.

19. Ardenkjær-Larsen JH, Fridlund B, Gram A, et al. Increase in signal-to-noise ratio of >10,000 times in liquid-state NMR. *Proc Natl Acad Sci USA*. 2003;100(18):10158-10163.

20. Larson PEZ, Gordon JW. Hyperpolarized metabolic MRI-acquisition, reconstruction, and analysis methods. *Metabolites*. 2021;11(6):386.

21. Louvet A, Mathurin P. Alcoholic liver disease: mechanisms of injury and targeted treatment. *Nat Rev Gastroenterol Hepatol*. 2015;12(2):231-242.

22. Stine JG, Chalasani N. Chronic liver injury induced by drugs: a systematic review. *Liver Int*. 2015;35(11):2343-2353.

23. Zhao RH, Shi Y, Zhao H, Wu W, Sheng JF. Acute-on-chronic liver failure in chronic hepatitis B: an update. *Expert Rev Gastroenterol Hepatol*. 2018;12(4):341-350.

24. Josan S, Billingsley K, Orduna J, et al. Assessing inflammatory liver injury in an acute CCl4 model using dynamic 3D metabolic imaging of hyperpolarized [1-(13)C]pyruvate. *NMR Biomed*. 2015;28(12):1671-1677.

25. Kim G-W, Oh C-H, Kim J-C, et al. Noninvasive biomarkers for acute hepatotoxicity induced by 1,3-dichloro-2-propanol: hyperpolarized 13C dynamic MR spectroscopy. *Magn Reson Imaging*. 2016;34(2):159-165.

26. Bahde R, Spiegel HU. Hepatic ischaemia–reperfusion injury from bench to bedside. *Br J Surg*. 2010;97(10):1461-1475.

27. Peralta C, Jiménez-Castro MB, Gracia-Sancho J. Hepatic ischemia and reperfusion injury: effects on the liver sinusoidal milieu. *J Hepatol*. 2013;59(5):1094-1106.

28. Josan S, Billingsley K, Orduna J, et al. Assessing inflammatory liver injury in an acute CCl4 model using dynamic 3D metabolic imaging of hyperpolarized [1-(13)C]pyruvate. *NMR Biomed*. 2015;28(12):1671-1677.

29. Lanitis S, Lolis E, Dafnios N, Sgourakis G, Voros DC, Vassiliou I. The effect of warm liver ischaemia & reperfusion injury on circulating plasma lipid levels & lipolytic enzyme activity in rat & the impact of ischaemic preconditioning. *Indian J Med Res*. 2012;136(2):272-279.

30. Moon C-M, Shin S-S, Lim N-Y, et al. Metabolic alterations in a rat model of hepatic ischaemia reperfusion injury: in vivo hyperpolarized 13C MRS and metabolic imaging. *Liver Int*. 2018;38(6):1117-1127.

31. Ratziu V, Goodman Z, Sanvay A. Current efforts and trends in the treatment of NASH. *Journal of Hepatology*. 2015;62(1,Supplement):S56-S57.

32. Keshari KR, Kurhanewicz J, Bok R, Larson PEZ, Vigneron DB, Wilson DM. Hyperpolarized 13C dehydroascorbate as an endogenous redox sensor for in vivo metabolic imaging. *Proc Natl Acad Sci USA*. 2011;108(46):18606-18611.

33. Wilson DM, Di Galle L, Wang ZJ, et al. Hyperpolarized 13C spectroscopic evaluation of oxidative stress in a rodent model of steatohepatitis. *Sci Rep*. 2017;7:46014.

34. Craig AJ, von Felden J, García-Lezana T, Sarcognato S, Villanueva A. Tumour evolution in hepatocellular carcinoma. *Nat Rev Gastroenterol Hepatol*. 2020;17(3):139-152.

35. Ye Y, Chen H-Y, Aggarwal R, et al. Hyperpolarized 13C-pyruvate MRI detects real-time metabolic flux in prostate cancer metastases to bone and liver: a clinical feasibility study. *Prostate Cancer Prostatic Dis*. 2020;23(2):269-276.

36. Ardenkjær-Larsen JH, Fridlund B, Gram A, et al. Increase in signal-to-noise ratio of >10,000 times in liquid-state NMR. *Proc Natl Acad Sci USA*. 2003;100(18):10158-10163.

37. Larson PEZ, Gordon JW. Hyperpolarized metabolic MRI-acquisition, reconstruction, and analysis methods. *Metabolites*. 2021;11(6):386.

38. Louvet A, Mathurin P. Alcoholic liver disease: mechanisms of injury and targeted treatment. *Nat Rev Gastroenterol Hepatol*. 2015;12(2):231-242.

39. Kim G-W, Oh C-H, Kim J-C, et al. Noninvasive biomarkers for acute hepatotoxicity induced by 1,3-dichloro-2-propanol: hyperpolarized 13C dynamic MR spectroscopy. *Magn Reson Imaging*. 2016;34(2):159-165.

40. Bahde R, Spiegel HU. Hepatic ischaemia–reperfusion injury from bench to bedside. *Br J Surg*. 2010;97(10):1461-1475.

41. Peralta C, Jiménez-Castro MB, Gracia-Sancho J. Hepatic ischemia and reperfusion injury: effects on the liver sinusoidal milieu. *J Hepatol*. 2013;59(5):1094-1106.

42. Lanitis S, Lolis E, Dafnios N, Sgourakis G, Voros DC, Vassiliou I. The effect of warm liver ischaemia & reperfusion injury on circulating plasma lipid levels & lipolytic enzyme activity in rat & the impact of ischaemic preconditioning. *Indian J Med Res*. 2012;136(2):272-279.

43. Moon C-M, Shin S-S, Lim N-Y, et al. Metabolic alterations in a rat model of hepatic ischaemia reperfusion injury: in vivo hyperpolarized 13C MRS and metabolic imaging. *Liver Int*. 2018;38(6):1117-1127.

44. Wang S, Friedman SL. Hepatic fibrosis: a convergent response to alteration in glycolysis that precede c-Myc-induced tumor formation and regression. *Cell Metab*. 2011;14(1):131-142.

45. Vander Heiden MG, Cantley LC, Thompson CB. Understanding the Warburg effect: the metabolic requirements of cell proliferation. *Science*. 2009;324(5930):1029-1033.

46. Menzel MI, Farrell EV, Janich MA, et al. Multimodal assessment of in vivo metabolism with hyperpolarized 1-13C MR spectroscopy and F-18-FDG PET imaging in hepatocellular carcinoma tumor-bearing rats. *J Nucl Med*. 2013;54(7):1113-1119.

47. Darpolor MM, Ye Y-F, Chua M-S, et al. In vivo MRSI of hyperpolarized [1-(13)C]pyruvate in rat hepatocellular carcinoma. *NMR Biomed*. 2011;24(5):506-513.

48. Yen Y-F, Le Roux P, Mayer D, et al. T2 relaxation times of C-13 metabolites in a rat hepatocellular carcinoma model measured in vivo using C-13-MRS of hyperpolarized 1-13C pyruvate. *NMR Biomed*. 2010;23(4):414-423.

49. Jensen PR, Serra SC, Miragoli L, et al. Hyperpolarized 1-13C(2) ethyl acetocetate is a novel diagnostic metabolic marker of liver cancer. *Int J Cancer*. 2015;136(4):E117-E126.

50. Na K, Lee EY, Lee HJ, et al. Human plasma carboxylesterase 1, a novel serologic biomarker candidate for hepatocellular carcinoma. *Proteomics*. 2009;9(16):3989-3999.

51. Vasuri F, Renzulli M, Fittipaldi S, et al. Pathobiological and radiological approach for hepatocellular carcinoma subclassification. *Sci Rep*. 2019;9(1):14749.

52. Bidkordi G, Benfeitas R, Klefstig M, et al. Metabolic network-based stratification of hepatocellular carcinoma reveals three distinct tumor subtypes. *Proc Natl Acad Sci USA*. 2018;115(50):E11874-E11883.

53. Gallagher FA, Woitek R, McLean MA, et al. Imaging breast cancer using hyperpolarized carbon-13 MRI. *Proc Natl Acad Sci USA*. 2020;117(4):2092-2098.

54. Bliemmsrieder E, Kaissis G, Grasheh M, et al. Hyperpolarized C-13 pyruvate magnetic resonance spectroscopy for in vivo metabolic phenotyping of rat HCC. *Sci Rep*. 2021;11(1):1191.

55. Waleta S, Wetterling M, Lehrke M, et al. High lactate levels predict likelihood of metastases, tumor recurrence, and restricted patient survival in human cervical cancers. *Cancer Res*. 2000;60(4):916-921.

56. Gallagher FA, Kettunen MI, Day SE, Lerche M, Brindle KM. 13C MR spectroscopy measurements of glutaminase activity in human
59. von Morze C, Larson PEZ, Hu S, et al. Imaging of blood flow using hyperpolarized [(13)C]urea in preclinical cancer models. J Magn Reson Imaging. 2011;33(3):692-697.

60. Ye Z, Cao L, Wei Y, et al. Preoperative prediction of hepatocellular carcinoma with highly aggressive characteristics using quantitative parameters derived from hepatobiliary phase MR images. Ann Transl Med. 2020;8(4):85.

61. Bode BP, Fuchs BC, Hurley BP, et al. Molecular and functional analysis of glutamine uptake in human hepatoma and liver-derived cells. Am J Physiol Gastrointest Liver Physiol. 2002;283(5):G1062-G1073.

62. Johansson E, Månsson S, Wirestam R, et al. Cerebral perfusion as a potential target of [1-13C]-alanine. Magn Reson Med. 2004;51(3):464-472.

63. Qin H, Tang S, Riselli AM, et al. Clinical translation of hyperpolarized 13C pyruvate and urea MRI for simultaneous metabolic and perfusion imaging. Magn Reson Med. 2022;87(1):138-149.

64. Llovet JM, Kelley RK, Villanueva A, et al. Hepatocellular carcinoma. Nat Rev Dis Primers. 2021;7(1):6.

65. Forner A, Ayuso C, Varela M, et al. Evaluation of tumor response after locoregional therapies in hepatocellular carcinoma: are response evaluation criteria in solid tumors reliable? Cancer. 2009;115(3):616-623.

66. Gallagher FA, Kettunen MI, Hu DE, et al. Production of hyperpolarized [1,4-13C2]malate from [1,4-13C2]fumarate is a marker of cell necrosis and treatment response in tumors. Proc Natl Acad Sci USA. 2009;106(47):19801-19806.

67. Cabella C, Karlsson M, Canape C, et al. In vivo and in vitro liver cancer metabolism observed with hyperpolarized 5-C-13 glutamine. J Magn Reson. 2013;232:45-52.

68. Zhu Z, Zhu X, Ohliger MA, et al. Coil combination methods for multi-channel hyperpolarized 13C imaging data from human studies. J Magn Reson. 2019;301:73-79.

69. Sánchez-Heredia JA-O, Baron R, Hansen ESS, Laustsen CA-O, Zhurbenko V, Ardenkjær-Larsen JA-O. Autonomous cryogenic RF receive coil for (13) C imaging of rodents at 3 T. Magn Reson Med. 2020;84(1):497-508.

70. Gordon JW, Chen HY, Dwork N, Tang S, Larson PA-O. Fast imaging for hyperpolarized MR metabolic imaging. Magn Reson Med. 2021;53(3):686-702.

71. Lee PM, Chen H-Y, Gordon JW, et al. Specialized computational methods for denoising, B-1 correction, and kinetic modeling in hyperpolarized C-13 MR EPSI studies of liver tumors. Magn Reson Med. 2021;86:2402-2411.

72. Ohliger MA, von Morze C, Marco-Rius I, et al. Combining hyperpolarized 13 C MRI with a liver-specific gadolinium contrast agent for selective assessment of hepatocyte metabolism. Magn Reson Med. 2017;77(6):2356-2363.

73. Marco-Rius I, Gordon JW, Mattis AN, et al. Diffusion-weighted imaging of hyperpolarized C-13 urea in mouse liver. J Magn Reson Imaging. 2018;47(1):141-151.

74. Gutte H, Hansen AE, Larsen MM, et al. Simultaneous hyperpolarized 13C-pyruvate MRI and 18F-FDG PET (HyperPET) in 10 dogs with cancer. J Nucl Med. 2015;56(11):1786-1792.

75. Marco-Rius I, Wright AJ, Hu D-e, et al. Probing hepatic metabolism of 2-C-13 dihydroxyacetone in vivo with(1)H-D-coupled hyperpolarized(13)C-MR. Magn Reson Mater Phys Biol Med. 2021;34(1):49-56.

76. Marco-Rius I, von Morze C, Sriram R, et al. Monitoring acute metabolic changes in the liver and kidneys induced by fructose and glucose using hyperpolarized [2-13 C]dihydroxyacetone. Magn Reson Med. 2017;77(1):65-73.

77. Park JM, Khemtong C, Liu S-C, Hurd RE, Spielman DM. In vivo assessment of intracellular redox state in rat liver using hyperpolarized [1-13 C]alanine. Magn Reson Med. 2017;77(5):1741-1748.

78. Dzien P, Kettunen MI, Marco-Rius I, et al. C-13 magnetic resonance spectroscopic imaging of hyperpolarized 1-C-13, U-H-2(5) ethanol oxidation can be used to assess aldehyde dehydrogenase activity in vivo. Magn Reson Med. 2015;73(5):1733-1740.

79. Chen J, Hackett EP, Kovacs Z, Malloy CR, Park JM. Assessment of hepatic pyruvate carboxylase activity using hyperpolarized [1-13 C]-l-lactate. Magn Reson Med. 2021;85(3):1175-1182.

80. Malloy CR. Effect of fatty liver on TCA cycle flux and the pentose phosphate pathway (HPFF). https://clinicaltrials.gov/ct2/show/NCT03480594?term=hyperpolarized&cond=liver &draw=2&rank=1

How to cite this article: Ye Z, Song B, Lee PM, Ohliger MA, Laustsen C. Hyperpolarized carbon 13 MRI in liver diseases: Recent advances and future opportunities. Liver Int. 2022;42:973–983. doi: 10.1111/liv.15222